Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center

New York, New York 10032

5 studies enrolling now · 11 studies all time

What they study most

Adenomatous Polyposis Coli, Advanced or Metastatic Colorectal Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-small-Cell Lung, Carcinoma, Squamous Cell, Colorectal Neoplasms, Hematological Malignancies, Major Depressive Disorder, Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Prostatic Neoplasms, Relapsed or Refractory Multiple Myeloma

Studies at this site

• A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer — Recruiting now
• A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
• A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer — Recruiting now
• JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC — Recruiting now
• A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer — Recruiting now
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer — Recruiting now
• A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma — Running, not enrolling
• Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer — Paused
• A Study of Guselkumab in Participants With Familial Adenomatous Polyposis — Completed
• Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies — Stopped early
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib — Stopped early